Ping Identity (NYSE:PING) vs. Oncology Pharma (OTCMKTS:ONPH) Head-To-Head Comparison

Ping Identity (NYSE:PINGGet Rating) and Oncology Pharma (OTCMKTS:ONPHGet Rating) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Ping Identity and Oncology Pharma’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ping Identity $299.45 million 5.29 -$64.39 million ($0.82) -22.65
Oncology Pharma N/A N/A N/A N/A N/A

Oncology Pharma has lower revenue, but higher earnings than Ping Identity.

Analyst Recommendations

This is a summary of current ratings and target prices for Ping Identity and Oncology Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ping Identity 0 4 10 1 2.80
Oncology Pharma 0 0 0 0 N/A

Ping Identity presently has a consensus target price of $33.00, indicating a potential upside of 77.90%. Given Ping Identity’s higher probable upside, research analysts clearly believe Ping Identity is more favorable than Oncology Pharma.

Insider and Institutional Ownership

84.3% of Ping Identity shares are held by institutional investors. 2.9% of Ping Identity shares are held by company insiders. Comparatively, 18.0% of Oncology Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Ping Identity and Oncology Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ping Identity -21.80% -4.99% -3.46%
Oncology Pharma N/A N/A N/A

Volatility and Risk

Ping Identity has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Oncology Pharma has a beta of -1.91, suggesting that its stock price is 291% less volatile than the S&P 500.

Summary

Ping Identity beats Oncology Pharma on 6 of the 10 factors compared between the two stocks.

About Ping Identity (Get Rating)

Ping Identity Holding Corp., doing business as Ping Identity Corporation, offers intelligent identity solutions for the enterprise in the United States and internationally. Its Ping Intelligent Identity platform provides access to cloud, mobile, Software-as-a-Service, and on-premise applications with customers, workforce, and partners. The company's platform offers secure single sign-on; multi-factor authentication; access security; directory solution; dynamic authorization; risk management; identity verification; API intelligence; orchestration; and fraud detection. It also provides professional and customer support services. The company sells its solutions through a direct sales force. Its customers include enterprises in Fortune 100, U.S. banks, healthcare companies, aerospace companies, auto manufacturers, and North American retailers. The company was formerly known as Roaring Fork Holding, Inc. and changed its name to Ping Identity Holding Corp. in August 2019. Ping Identity Holding Corp. was incorporated in 2016 and is headquartered in Denver, Colorado.

About Oncology Pharma (Get Rating)

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.

Receive News & Ratings for Ping Identity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ping Identity and related companies with MarketBeat.com's FREE daily email newsletter.